KRAS G12C inhibitor chemical landscape

KRAS inhibitorRefresh recommended

Shared acrylicamide / warhead chemotype from core scaffold to sotorasib, adagrasib, daraxonrasib and SAR analogs.

Mechanism · KRAS inhibitor BioMoa · KRAS inhibitor 프로그램 BioMoa bridge · shared ID

Last analysis: 7/20/2026, 2:08:56 AM · 2 weeks cadence · refresh on /analyze · refresh recommended

Data sources: Catalog seed · PubChem · ChEMBL · ClinicalTrials.gov · FDA/EMA · FDA
Last updated: 7/20/2026, 2:08:56 AM
Similarity method: Morgan fingerprint, radius 2, 2048 bits, Tanimoto
Verified / known compounds: 6
Exploratory nodes: 6
Abstract scaffolds: 1
Relationship types: Derived (curated) · Fingerprint similarity · Drug-class link

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Spider Web · Flow · Structure table · Compare · SMILES map

Name, 2D structure, SMILES, role, parent, core similarity, and traits. Click a row for details.

Compound	Role	SMILES	Parent	Core sim.	Traits
KRAS G12C warhead (acrylamide pharmacophore)Abstract pharmacophorekras-g12c-warheadPage	Scaffold	`C=CC(=O)Nc1ccc(F)cc1`	—	—	KRAS G12C · covalent · core · warhead · Hinge-binding acrylamide — common origin for covalent G12C series.
Adagrasib (Krazati)Verified drugadagrasibPage	Drug	`CC(C)C1=NC(=C(N1)C2=CC=CC=C2)C3=CC4=C(C=C3…`	KRAS G12C warhead (acrylamide pharmacophore)	13%i	approved · KRAS G12C · Krazati · KRAS G12C inhibitor with long half-life (Krazati). · CHEMBL4594350 · CID 138565341
DaraxonrasibKnown compounddaraxonrasib-kras-nodePage	Drug	`C[C@H]1CN(C(=O)C2=C(NC3=CC=CC(F)=C3)N=C(N2…`	KRAS G12C warhead (acrylamide pharmacophore)	16%i	KRAS G12C · clinical · Clinical-stage candidate. Daraxonrasib in this family map.
Divarasib (GDC-6036)Known compounddivarasibPage	Drug	`C[C@H]1CN(C(=O)C2=C(NC3=CC=CC(F)=C3)N=C(N2…`	KRAS G12C warhead (acrylamide pharmacophore)	16%i	KRAS G12C · clinical · Clinical-stage candidate. Divarasib (GDC-6036) in this family map.
Garsorasib (D-1553)Known compoundgarsorasibPage	Drug	`C[C@H]1CN(C(=O)c2ccc(F)cc2NC(=O)C3=C(Nc4cc…`	KRAS G12C warhead (acrylamide pharmacophore)	20%i	KRAS G12C · clinical · Clinical KRAS G12C inhibitor (D-1553) — distinct chemotype from sotorasib.
Olomorasib (LY3537982)Known compoundolomorasibPage	Drug	`C[C@H]1CN(C(=O)C2=C(NC3=CC=CC(Cl)=C3)N=C(N…`	KRAS G12C warhead (acrylamide pharmacophore)	12%i	clinical · KRAS G12C · Clinical-stage candidate. Olomorasib (LY3537982) in this family map.
Sotorasib (Lumakras)Verified drugsotorasibPage	Drug	`C[C@H]1CN(C(=O)C2=C(NC3=CC=CC(F)=C3)N=C(N2…`	KRAS G12C warhead (acrylamide pharmacophore)	16%i	approved · KRAS G12C · Lumakras · First approved covalent KRAS G12C inhibitor (Lumakras). · CHEMBL4297837 · CID 118023034
KRAS chloro-bridge analogExploratory analog (rule-generated)kras-sar-cl-bridgePage	Derivative	`C=CC(=O)Nc1ccc(F)cc1NCc1ccc(Cl)cc1`	KRAS SAR analog B (from analog A)	42%i	SAR · SAR exploration node. Derived analog of parent node in KRAS G12C inhibitor chemical landsc…
KRAS piperazine SAR analogExploratory analog (rule-generated)kras-sar-piperazinePage	Derivative	`C=CC(=O)Nc1ccc(F)cc1N1CCNCC1`	KRAS SAR analog A (F-aryl walk)	43%i	SAR · SAR exploration node. Derived analog of parent node in KRAS G12C inhibitor chemical landsc…
KRAS PROTAC hybrid 1Exploratory analogkras-protac-1Page	Derivative	`C[C@H]1CN(C(=O)C2=C(NC3=CC=CC(F)=C3)N=C(N2…`	Sotorasib (Lumakras)	12%i	PROTAC · degrader · SAR / analog node exploring potency, selectivity, or ADME.
KRAS SAR analog A (F-aryl walk)Exploratory analog (rule-generated)kras-sar-analog-aPage	Derivative	`C=CC(=O)Nc1ccc(F)cc1NC2=CC=CC=C2`	KRAS G12C warhead (acrylamide pharmacophore)	51%i	SAR · derivative · SAR exploration node. Derived analog of parent node in KRAS G12C inhibitor chemical landsc…
KRAS SAR analog B (from analog A)Exploratory analog (rule-generated)kras-sar-analog-bPage	Derivative	`C=CC(=O)Nc1ccc(F)cc1NC2=CC=C(Cl)C=C2`	KRAS SAR analog A (F-aryl walk)	53%i	SAR · ADME · SAR exploration node. Derived analog of parent node in KRAS G12C inhibitor chemical landsc…
KRAS-targeted payload analog 1Payloadkras-adc-payload-1Page	Payload	`C=CC(=O)Nc1ccc(F)cc1NC(=O)CCN`	KRAS G12C warhead (acrylamide pharmacophore)	45%i	payload · ADC-design · Payload warhead chemistry. Released warhead after lysosomal cleavage.

From the core chemical, derivatives, drugs, and payloads fan out. Dashed orange chords are drug–drug links (spider web).

Loading map…

Clinical · regulatory context

KRAS G12C — 승인 + 차세대

Sotorasib·adagrasib 승인. 구조 이웃은 종종 다른 돌연변이·RAS(ON) 임상 단계입니다.

Approved/clinical labels here come from the catalog clinical overlay. Agency names are shown when curated; live FDA/EMA APIs are not called.

SotorasibApprovedFDA/EMA
KRAS G12C NSCLC (and expansions)
ClinicalTrials.gov
AdagrasibApprovedFDA
KRAS G12C NSCLC
ClinicalTrials.gov

Program and pipeline notes live on BioMoa · kras-g12c · StructureMoa ↔ BioMoa bridge